Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc senior officer Walter Matthew R., SVP and Chief HR Officer, increased his direct equity stake through performance-based awards. On May 26, 2026, he acquired 9,149 ordinary shares via the exercise or settlement of awards and held 41,529 ordinary shares afterward.
The filing also shows the exercise of 8,449 Performance Share Units, each representing a contingent right to one Medtronic share. These units were originally granted on July 31, 2023, vested on April 24, 2026, and were settled based on performance certified on May 26, 2026. No open-market purchases or sales were reported; this reflects compensation vesting rather than trading.
Medtronic plc executive Brett A. Wall, EVP & President of Neuroscience, exercised performance-based share units that were granted on July 31, 2023. This settlement delivered 24,214 ordinary shares after performance was certified on May 26, 2026, following vesting on April 24, 2026.
After these transactions, Wall directly holds 82,183 Medtronic ordinary shares, which the disclosure notes include 527 shares acquired through dividend reinvestment since his prior report. The activity reflects compensation-related equity vesting rather than an open-market purchase or sale.
Medtronic plc Chairman and CEO Geoffrey Martha reported a compensation-related equity transaction involving performance share units. On May 26, 2026, he exercised performance-vesting share units into 85,461 Ordinary Shares, with the performance share units having fully vested on April 24, 2026. A related entry shows 94,963 Ordinary Shares credited, and his direct holdings after these transactions total 343,099 Ordinary Shares, which include 1,743 shares acquired through dividend reinvestment since his last report. Each performance share unit represented a contingent right to receive one Medtronic ordinary share, granted on July 31, 2023 and settled based on performance certified on May 26, 2026. The filing does not report any open‑market purchases or sales, only the exercise and settlement of equity awards.
Medtronic plc executive Michael Marinaro, EVP and President of MedSurg and Americas, reported the settlement of performance-based equity awards rather than an open-market trade. On May 26, 2026, he acquired 18,994 Ordinary Shares in connection with the exercise or conversion of derivative awards. These shares were issued upon settlement of performance-vesting share units that were granted on July 31, 2023, with performance certified on May 26, 2026, and that vested on April 24, 2026. Following these transactions, he directly owns 70,593 Medtronic shares.
Medtronic plc executive Harry "Skip" Kiil increased his direct Medtronic shareholding through equity compensation. On May 26, 2026, he acquired 15,195 Ordinary Shares, representing shares issued upon settlement of previously granted performance-vesting share units. These awards were granted on July 31, 2023, vested on April 24, 2026, and were settled after performance was certified on May 26, 2026. Following the transaction, Kiil directly holds 48,233 Ordinary Shares, reflecting compensation-based share delivery rather than an open-market purchase or sale.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported compensation-related share activity. On May 26, 2026, she acquired 1,712 Ordinary Shares through the exercise or settlement of derivative awards. A related Performance Share Unit award covering 1,621 units converted into Ordinary Shares, leaving no remaining units from that grant. Following these transactions, she directly holds 14,974 Ordinary Shares. Footnotes state that 1,027 of the shares issued from the performance-vesting units will be delivered when her employment with Medtronic ends, underscoring that this is a structured equity award rather than an open-market trade.
Medtronic plc reported a leadership change in its Neuroscience Portfolio. Brett Wall will depart his role as Executive Vice President and President, Neuroscience Portfolio, and remain with the company until September 1, 2026 to support an orderly transition. Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will become Executive Vice President and President, Neuroscience Portfolio effective June 1, 2026. Mr. Wall will receive severance payments and benefits consistent with Medtronic’s standard executive officer severance practices described in its 2025 proxy statement.
Medtronic plc SVP and Chief HR Officer Walter Matthew R. reported a small, routine tax-related share disposition. On the vesting of previously granted restricted stock units, 35 Ordinary Shares were withheld at $80.00 per share to cover taxes. Following this withholding, he directly holds 32,380 Ordinary Shares, which the footnotes state include 367 shares from dividend reinvestment and 191 shares acquired under Medtronic's Employee Stock Ownership Plan. This event reflects compensation and tax mechanics rather than an open-market stock sale.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported routine equity compensation activity. On April 27, 2026, she acquired 1,508 Ordinary Shares at $0.00 per share as a grant of restricted stock units that vest in three annual installments beginning one year from the grant date.
On April 28, 2026, 318 Ordinary Shares were disposed of at $81.90 per share, representing shares withheld to pay taxes upon vesting of previously granted restricted stock units, rather than an open-market sale. After these transactions, she directly owned 13,262 Ordinary Shares, including 106 shares acquired through dividend reinvestment since her last report.
Medtronic plc director Kendall J. Powell reported routine equity compensation activity. On April 27, 2026, he received a grant of 2,111 ordinary shares in the form of restricted stock units, which vest on the one-year anniversary of the award date. When previously granted restricted stock units vested, 207 shares of Medtronic ordinary shares were withheld at $81.90 per share to cover tax obligations rather than sold on the open market. After these transactions, Powell directly holds 51,380 ordinary shares, including 854 shares acquired through dividend reinvestment since his last report.